Wexler H, Carter W T, Harris B, Finegold S M
Antimicrob Agents Chemother. 1984 Feb;25(2):162-4. doi: 10.1128/AAC.25.2.162.
The in vitro activities of two new antimicrobial agents, apalcillin and cefpiramide (SM-1652), were evaluated against 324 strains of anaerobic bacteria. Apalcillin (a penicillin derivative) and cefpiramide (a semisynthetic cephalosporin) were compared with piperacillin, moxalactam, and cefoxitin. Organisms studied included the Bacteroides fragilis group, other Bacteroides species, fusobacteria, clostridia, nonsporeforming gram-positive rods, and anaerobic cocci. Piperacillin was found to be the most active overall, inhibiting 96% of the strains tested at its achievable level in serum (128 micrograms/ml). Apalcillin was comparable in activity to piperacillin, inhibiting 93% of anaerobes tested at this concentration. The other antibiotics inhibited ca. 80% of the strains at 32 micrograms/ml. In terms of activities against particular species, apalcillin was active against 75% of B. fragilis group strains and 97 to 100% of all other anaerobes. Cefpiramide inhibited 37% of B. fragilis group strains at 32 micrograms/ml and 68% at 64 micrograms/ml (a level that may be achievable with this drug). Cefpiramide inhibited 92% of all other anaerobes at 32 micrograms/ml and 95% at 64 micrograms/ml. The clostridia other than Clostridium perfringens were the most resistant (84% inhibited at 32 micrograms/ml and 95% inhibited at 64 micrograms/ml).
对两种新型抗菌药物阿帕西林和头孢匹胺(SM-1652)针对324株厌氧菌的体外活性进行了评估。将阿帕西林(一种青霉素衍生物)和头孢匹胺(一种半合成头孢菌素)与哌拉西林、拉氧头孢和头孢西丁进行了比较。所研究的微生物包括脆弱拟杆菌群、其他拟杆菌属、梭杆菌属、梭菌属、无芽孢革兰氏阳性杆菌和厌氧球菌。发现哌拉西林总体活性最高,在血清中可达到的水平(128微克/毫升)下抑制了96%的测试菌株。阿帕西林的活性与哌拉西林相当,在此浓度下抑制了93%的测试厌氧菌。其他抗生素在32微克/毫升时抑制了约80%的菌株。就对特定菌种的活性而言,阿帕西林对75%的脆弱拟杆菌群菌株和97%至100%的所有其他厌氧菌有活性。头孢匹胺在32微克/毫升时抑制了37%的脆弱拟杆菌群菌株,在64微克/毫升时抑制了68%(该药物可能达到的水平)。头孢匹胺在32微克/毫升时抑制了92%的所有其他厌氧菌,在64微克/毫升时抑制了95%。除产气荚膜梭菌外的梭菌属对药物最耐药(在32微克/毫升时84%被抑制,在64微克/毫升时95%被抑制)。